Modulators of pharmacokinetic properties of therapeutics

Abstract

or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.

1 - 20 . (canceled) 
     
     
         21 . An in vivo metabolic product of Compound P prepared according to the process of Scheme 18 at page 211. 
     
     
         22 . The metabolic product of  claim 21  which is substantially isolated. 
     
     
         23 . A method of preparing the in vivo metabolic product of  claim 21  comprising contacting Compound P prepared according to the process of Scheme 18 at page 211 with a mammal for a period of time sufficient to yield the in vivo metabolic product. 
     
     
         24 . The method of  claim 23  wherein the mammal is a rat, mouse, guinea pig, monkey, or human. 
     
     
         25 . The method of  claim 23  wherein Compound P prepared according to the process of Scheme 18 at page 211 is orally administered to the mammal. 
     
     
         26 . The method of  claim 23  wherein Compound P prepared according to the process of Scheme 18 at page 211 is radiolabeled. 
     
     
         27 . The method of  claim 26  wherein the radiolabel comprises C 14  or H 3 . 
     
     
         28 . A method of determining the optimal therapeutic dose of Compound P prepared according to the process of Scheme 18 at page 211 in a mammal comprising measuring the quantity of the in vivo metabolic product of  claim 21  produced upon contacting the mammal with a radiolabeled Compound P and correlating the measured quantity of the in vivo metabolic product with therapeutic effectiveness of Compound P. 
     
     
         29 . A prodrug of Compound P prepared according to the process of Scheme 18 at page 211. 
     
     
         30 . A pharmaceutical composition comprising the prodrug of  claim 29 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. 
     
     
         31 . A method of improving the pharmacokinetics of a drug, comprising administering to a patient treated with said drug, a therapeutically effective amount of a prodrug of  claim 29 , or a pharmaceutically acceptable salt thereof. 
     
     
         32 . A solvate of Compound P prepared according to the process of Scheme 18 at page 211. 
     
     
         33 . A pharmaceutical composition comprising the solvate of  claim 32 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. 
     
     
         34 . A method of improving the pharmacokinetics of a drug, comprising administering to a patient treated with said drug, a therapeutically effective amount of a solvate of  claim 32 , or a pharmaceutically acceptable salt thereof. 
     
     
         35 . A kit comprising Compound P prepared according to the process of Scheme 18 at page 211, wherein the kit is useful for improving the pharmacokinetics of a drug.